Alefacept (Amevive)

A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.

Also Known As:

Networked: 234 relevant articles (56 outcomes, 68 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gottlieb, Alice B: 9 articles (09/2011 - 11/2003)
2.	Korman, Neil J: 9 articles (09/2011 - 03/2005)
3.	Krueger, Gerald G: 9 articles (01/2008 - 04/2002)
4.	Lebwohl, Mark: 8 articles (03/2010 - 03/2003)
5.	Weinberg, Jeffrey M: 8 articles (06/2009 - 12/2002)
6.	Feldman, Steven R: 7 articles (12/2012 - 01/2006)
7.	Alefacept Clinical Study Group: 7 articles (06/2010 - 07/2001)
8.	Gordon, Kenneth B: 7 articles (09/2009 - 11/2003)
9.	Shear, Neil H: 6 articles (08/2012 - 01/2006)
10.	Menter, Alan: 6 articles (10/2009 - 03/2003)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 12/01/2015 - "Phase II and phase III clinical trials of alefacept with psoriasis patients demonstrated promising results and an excellent safety profile. " 08/01/2003 - "We conclude that alefacept significantly improves psoriasis and produces durable clinical improvement with a very favorable safety profile." 01/01/2003 - "black triangle In placebo-controlled studies, once-weekly administration of alefacept 7.5mg intravenous (IV) and 15mg intramuscular (IM) for 12 weeks significantly improved psoriasis and produced durable clinical improvements in patients with moderate-to-severe chronic plaque psoriasis who responded. " 12/01/2002 - "In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. " 03/01/2008 - "The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis."
2.	Psoriatic Arthritis 10/01/2005 - "In addition, data are reviewed on the use of alefacept in combination with other agents and in other diseases, including psoriatic arthritis." 10/01/2004 - "A preliminary study evaluating the use of alefacept for the treatment of active psoriatic arthritis parallels the psoriasis experience and supports the premise of targeting T cells as an intervention for this disease. " 11/01/2005 - "This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis." 11/01/2005 - "Alefacept for psoriasis and psoriatic arthritis." 10/01/2002 - "Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis."
3.	Vitiligo 02/01/2013 - "To evaluate the safety and efficacy of alefacept in the treatment of vitiligo. " 02/01/2013 - "Alefacept as a monotherapy for vitiligo treatment did not result in any patient improvement, and further evaluation in larger studies may be required." 02/01/2013 - "Failure of alefacept in the treatment of vitiligo." 05/01/2009 - "Use of alefacept in vitiligo may turn out to be a possible novel off-label treatment option in vitiligo. " 02/01/2013 - "After providing informed written consent, 4 adult patients with widespread vitiligo (covering a body surface area ≥5%) were treated with weekly intramuscular injections of 15 mg alefacept for 12 weeks. "
4.	Graft vs Host Disease (Graft-Versus-Host Disease) 06/01/2007 - "Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. " 10/01/2015 - "Three multiply transfused pediatric patients with NMD received a short course of high-dose i.v. alefacept (.25 mg/kg/dose on days -40 and -9 and .5 mg/kg/dose on days -33, -26, -19, and -12) before undergoing unrelated allogeneic transplant in the setting of reduced-intensity pretransplant conditioning and calcineurin inhibitor-based post-transplant graft-versus-host disease (GVHD) prophylaxis. " 01/01/2007 - "Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity." 12/01/2005 - "Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report." 01/01/2009 - "We have shown previously that alefacept is effective in acute steroid resistant/dependent and chronic extensive graft versus host disease (GvHD) with a protocol using timings similar to those used for psoriasis treatment. "
5.	Alopecia Areata 11/01/2009 - "To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA). " 11/01/2009 - "Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study." 12/01/2005 - "Alefacept for alopecia areata." 10/01/2004 - "Research continues to examine the use of alefacept in combination with other systemic psoriasis therapies and phototherapy and its potential as a treatment for other T-cell-mediated diseases, such as psoriatic arthritis, alopecia areata, and rheumatoid arthritis." 01/01/2007 - "Reported effective off-label uses of alefacept include: generalized lichen planus, alopecia areata, steroid-resistant or steroid-dependent acute graft-versus-host disease, scleroderma, nail psoriasis, and palmoplantar psoriasis."

Related Drugs and Biologics

1.	Infliximab (Remicade)
2.	efalizumab (Raptiva)
3.	Etanercept (Enbrel)
4.	Adalimumab (Humira)
5.	Ustekinumab (CNTO 1275)
6.	Methotrexate (Mexate)
7.	Alefacept (Amevive)
8.	Rituximab (Mabthera)
9.	Prostaglandins A
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Phototherapy (Light Therapy)
3.	Withholding Treatment
4.	Biological Therapy
5.	Drug Therapy (Chemotherapy)